Zura Bio (ZURA) Price & Analysis

Compare

458 Followers

ZURA Stock Chart & Stats

$3.21

-$0.21(-8.71%)

At close: Jan 08 4:00 PM EST

$3.21

-$0.21(-8.71%)

Day’s Range― - ―

52-Week Range$0.97 - $4.98

Previous CloseN/A

Volume136.30K

Average Volume (3M)2.99M

Market Cap

$208.71M

Enterprise Value-$42.28M

Total Cash (Recent Filing)$154.49M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.40

Next Earnings

Nov 17, 2025

EPS Estimate

-0.18

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.17

Shares Outstanding65,018,060

10 Day Avg. Volume1,304,161

30 Day Avg. Volume2,987,270

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.20

Enterprise Value/Revenue-21.14K

Enterprise Value/Gross Profit1.92K

Enterprise Value/Ebitda0.60

Forecast

1Y Price Target

$9.00

Price Target Upside180.37% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Clinical ProgressPh 2 studies for lead asset tibulizumab (IL17A / BAFF bispecific) remain on track in systemic sclerosis (SSc) and hidradenitis suppurativa (HS) with data expected 2H26.

Market ValidationNVS shared that ianalumab demonstrated efficacy vs. placebo, which bolsters ZURA's hypothesis for tibu in HS.

Therapeutic MechanismThe dual-mechanism of ZURA's tibulizumab in HS is believed to offer a solid chance to improve on current and emerging standards of care.

Bears Say

Clinical Data ConcernsReservations exist ahead of clinical data for tibulizumab, including lackluster clinical data generated to date, with no clear dose-dependent response in B cell count reductions and a rise in IL-17A target engagement observed at the highest dose.

CompetitionThe market for HS treatment is increasingly competitive, with dual IL-17A/F inhibitors showing impressive efficacy and setting a high benchmark that could overshadow older treatments like tibulizumab.

Financial OutlookFinancial results reported show a reduction in cash and cash equivalents and an increase in potentially dilutive shares outstanding, leading to a reduced 12-month price target.

Zura Bio News

Zura Bio CEO Takes Medical Leave, Interim Appointed

Zura Bio ( ($ZURA) ) has issued an announcement. On October 8, 2025, Zura Bio Limited announced that...

11d ago

ZURA

Zura Bio Implements Executive Severance Benefit Plan

Zura Bio ( ($ZURA) ) has issued an update. On September 24, 2025, Zura Bio Limited’s Board of...

20d ago

ZURA

Zura Bio Unveils Updated Corporate Presentation

Zura Bio ( ($ZURA) ) just unveiled an announcement. On September 4, 2025, Zura Bio Limited announced an...

2M ago

ZURA

Zura Bio to Attend Global Healthcare Conference

An announcement from Zura Bio ( ($ZURA) ) is now available. On August 20, 2025, Zura Bio announced...

2M ago

ZURA

Zura Bio price target lowered to $2 from $3 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Zura Bio (ZURA) to $2 from $3 and keeps a...

2M ago

ZURA

Zura Bio price target lowered to $16 from $17 at Oppenheimer

Oppenheimer lowered the firm’s price target on Zura Bio (ZURA) to $16 from $17 and keeps an Outperform...

2M ago

ZURA

Zura Bio Limited Reports Q2 2025 Financial Results

Zura Bio Limited ( ($ZURA) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

ZURA

Novartis trial has positive read for Zura Bio, says Guggenheim

After Novartis (NVS) announced that both of two Phase 3 trials evaluating ianalumab in adults with active Sjogren’s...

2M ago

NVS

ZURA

Cautious Outlook for Zura Bio Amid Competitive Challenges and Historical Concerns

Zura Bio, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mitchell Kapoor from...

3M ago

ZURA

Zura Bio Appoints New CFO Eric Hyllengren

Zura Bio ( ($ZURA) ) has provided an update. On July 1, 2025, Zura Bio announced the appointment...

4M ago

ZURA

Zura Bio appoints Eric Hyllengren as CFO

Zura Bio (ZURA) appointed Eric Hyllengren as CFO, effective July 7. He will succeed Verender Badial, who will...

4M ago

ZURA

Zura Bio participates in a conference call with Piper Sandler

Conference call with management will be held on June 17 hosted by Piper Sandler. Published first on TheFly...

4M ago

ZURA

Zura Bio Highlights Pipeline Progress at Jefferies Conference

An update from Zura Bio ( ($ZURA) ) is now available. On June 4, 2025, Zura Bio Limited...

5M ago

ZURA

Zura Bio to Present at Jefferies Healthcare Conference

The latest update is out from Zura Bio ( ($ZURA) ). On May 27, 2025, Zura Bio announced...

5M ago

ZURA

ZURA FAQ

What was Zura Bio’s price range in the past 12 months?

Zura Bio lowest stock price was $0.97 and its highest was $4.98 in the past 12 months.

What is Zura Bio’s market cap?

Zura Bio’s market cap is $208.71M.

When is Zura Bio’s upcoming earnings report date?

Zura Bio’s upcoming earnings report date is Nov 17, 2025 which is in 27 days.

How were Zura Bio’s earnings last quarter?

Zura Bio released its earnings results on Aug 14, 2025. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.188 by $0.018.

Is Zura Bio overvalued?

According to Wall Street analysts Zura Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Zura Bio pay dividends?

Zura Bio does not currently pay dividends.

What is Zura Bio’s EPS estimate?

Zura Bio’s EPS estimate is -0.18.

How many shares outstanding does Zura Bio have?

Zura Bio has 65,018,060 shares outstanding.

What happened to Zura Bio’s price movement after its last earnings report?

Zura Bio reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.188. Following the earnings report the stock price went up 8.176%.

Which hedge fund is a major shareholder of Zura Bio?

Currently, no hedge funds are holding shares in ZURA

Zura Bio Stock Smart Score

Neutral

Fundamentals

Return on Equity

-46.33%

Trailing 12-Months

Asset Growth

-16.73%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

Zura Bio (ZURA) Earnings & Revenues

Historic Earnings Reports

ZURA Stock 12 Month Forecast

Average Price Target

$9.00

▲(180.37% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","17":"$17","4.25":"$4.25","8.5":"$8.5","12.75":"$12.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.25,8.5,12.75,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.02,3.0953846153846154,4.170769230769231,5.246153846153846,6.321538461538461,7.396923076923077,8.472307692307693,9.547692307692307,10.623076923076923,11.698461538461538,12.773846153846154,13.849230769230768,14.924615384615384,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.02,2.556923076923077,3.0938461538461537,3.6307692307692307,4.167692307692308,4.704615384615385,5.241538461538461,5.7784615384615385,6.315384615384616,6.852307692307692,7.389230769230769,7.926153846153847,8.463076923076922,{"y":9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.02,2.0184615384615383,2.016923076923077,2.0153846153846153,2.013846153846154,2.0123076923076924,2.0107692307692306,2.0092307692307694,2.0076923076923077,2.006153846153846,2.0046153846153847,2.003076923076923,2.0015384615384617,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.25,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.76,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.13,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.85,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.38,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.5,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.36,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.02,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >